Europe CAR-T Cell Therapy Market
The Europe CAR-T Cell Therapy market was valued at USD 296.21 Mn in 2020 which expected to reach USD 1,904.40 Mn by 2027 at a CAGR 30.45% from 2020-2027.
The CAR-T Cell Therapy market is a conceptual examination of all commercial activities related to CAR-T Cell Therapy, either directly or indirectly. As a result, a new investor can learn about CAR-T Cell Therapy firms, their important products, their basic strategy, key CAR-T Cell Therapy market trends, and more.
Market Drivers
Increasing approvals for CAR-T cell therapy products.
Increase in awareness about the new approach to treat cancer leads to increase in demand for the CAR-T cell therapy products. Thus, the key players in market are engaged in developing new products & thereby drive the growth of Europe CAR-T Cell Market.
For Instance, in June 2020, Kite Pharma, received approval to implement a variation to the Yescarta (axicabtagene ciloleucel) Marketing Authorization from the European Medicine Agency for end-to-end manufacturing. With this approval, Kite’s European manufacturing facility, designed & dedicated to the manufacture of individualized cell therapies, is now fully operational.
Market Restraints
CAR T therapies often come with unique drug development challenges. Some potential challenges associated with CAR T development is likely to hamper the growth of the Europe CAR-T Cell Therapy market. The potential challenges include limited guidance, manufacturing and distribution logistics, products safety etc.
Moreover, high cost involved in research & development for CAR-T cell therapies & lack of expertise as well as inadequate knowledge about CAR-T cell therapies are the major factors among others acting as restraints, and will further challenge the market in the forecast period.
Impact of COVID-19
Many businesses have seen their operations & financial performance suffer as a result of the COVID–19 pandemic and a slowing of global research activity. The negative impact is mostly due to the closure of academic & research institutes, as well as testing laboratories. As a result, the clinical trials conducted for the car T cell therapy has been delayed.
COVID-19 is posing a significant threat to health of vulnerable patients, like immunocompromised patients. CAR-T-cell therapy recipients are at high risk of poor COVID-19 due to their severely immunocompromised state, caused by prior lymphodepleting immunochemotherapy & CAR-T-cell therapy related side effects like B-cell depletion, hypogammaglobulinemia, and cytopenias.
Market Segmentation
The Europe CAR-T Cell Therapy Market is segmented into Type, Application, End-user and Growing System. By Type such as Abecma, Breyanzi , Kymriah, Tecartus, Yescarta. Further, market is segmented into By Application such as Cancer, Lymphoma, Others. By End-user such as Hospitals, Specialty Clinics, Others.
Country Analysis
Europe CAR-T Cell Therapy Market is segmented into fifteen regions such as Germany, France, UK, Turkey, Switzerland, Norway, Sweden, Spain, Denmark, Finland, Iceland, Poland, Luxembourg, Netherlands, and Belgium. Germany dominated the market and accounted for the largest revenue share of 15.10% in 2020. The region is expected to continue its dominance over the forecast period. UK is expected to grow at significant growth rate, as end-user such as Hospitals and Specialty Clinics segment are growing in the country. Due to rapid advances in the healthcare infrastructure and disposable income, the market
Key Players
Various key players are listed in this report such as Mustang Bio Inc, Calgene Corporation, Bluebird Bio Inc., Kite Pharma, Inc, CARsgen Therapeutics, Ltd., Legend Biotech, Immune Therapeutics, Pfizer Inc, Bellicum Pharmaceuticals, Inc, Sorrento Therapeutics, Inc, Novartis.
Market Taxonomy
By Type
By Application
By End-user
By Country
Key Questions Addressed by the Report
Europe CAR-T Cell Therapy Market TOC
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Europe CAR-T Cell Therapy Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Europe CAR-T Cell Therapy Market, By Type
5.1 Y-o-Y Growth Comparison, By Type
5.2 Europe CAR-T Cell Therapy Market Share Analysis, By Type
5.3 Europe CAR-T Cell Therapy Market Size and Forecast, By Type
5.3.1 Abecma
5.3.2 Breyanzi
5.3.3 Kymriah
5.3.4 Tecartus
5.3.5 Yescarta
6 Europe CAR-T Cell Therapy Market, By Application
6.1 Y-o-Y Growth Comparison, By Application
6.2 Europe CAR-T Cell Therapy Market Share Analysis, By Application
6.3 Europe CAR-T Cell Therapy Market Size and Forecast, By Application
6.3.1 Cancer
6.3.2 Lymphoma
6.3.3 Others
7 Europe CAR-T Cell Therapy Market, By End-user
7.1 Y-o-Y Growth Comparison, By End-user
7.2 Europe CAR-T Cell Therapy Market Share Analysis, By End-user
7.3 Europe CAR-T Cell Therapy Market Size and Forecast, By End-user
7.3.1 Hospitals
7.3.2 Specialty Clinics
7.3.3 Others
8 Europe CAR-T Cell Therapy Market, By Region
8.1 Europe CAR-T Cell Therapy Market Share Analysis, By Region
9 Europe CAR-T Cell Therapy Market Analysis and Forecast (2021-2027)
9.1 Introduction
9.2 Europe CAR-T Cell Therapy Market Share Analysis, By Type
9.3 Europe CAR-T Cell Therapy Market Size and Forecast, By Application
9.4 Europe CAR-T Cell Therapy Market Size and Forecast, By End-user
9.6 Europe CAR-T Cell Therapy Market Size and Forecast, By Country
9.7.1 Germany
9.7.2 France
9.7.3 UK
9.7.4 Turkey
9.7.5Switzerland
9.7.6 Norway
9.7.7 Sweden
9.7.8 Spain
9.7.9 Denmark
9.7.10 Finland
9.7.11 Iceland
9.7.12 Poland
9.7.13 Luxembourg
9.7.14 Netherlands
9.7.15 Belgium
10 Competitive Analysis
10.1 Competition Dashboard
10.2 Market share Analysis of Top Vendors
10.3 Key Development Strategies
10 Company Profiles
10.1 Mustang Bio Inc
10.1.1 Overview
10.1.2 Offerings
10.1.3 Key Financials
10.1.4 Business Segment & Geographic Overview
10.1.5 Key Market Developments
10.1.6 Key Strategies
10.2. Calgene Corporation
10.2.1 Overview
10.2.2 Offerings
10.2.3 Key Financials
10.2.4 Business Segment & Geographic Overview
10.2.5 Key Market Developments
10.2.6 Key Strategies
10.3. Bluebird Bio Inc.
10.3.1 Overview
10.3.2 Offerings
10.3.3 Key Financials
10.3.4 Business Segment & Geographic Overview
10.3.5 Key Market Developments
10.3.6 Key Strategies
10.4 Kite Pharma, Inc
10.4.1 Overview
10.4.2 Offerings
10.4.3 Key Financials
10.4.4 Business Segment & Geographic Overview
10.4.5 Key Market Developments
10.4.6 Key Strategies
10.5 . CARsgen Therapeutics, Ltd.
10.5.1 Overview
10.5.2 Offerings
10.5.3 Key Financials
10.5.4 Business Segment & Geographic Overview
10.5.5 Key Market Developments
10.5.6 Key Strategies
10.6 Legend Biotech
10.6.1 Overview
10.6.2 Offerings
10.6.3 Key Financials
10.6.4 Business Segment & Geographic Overview
10.6.5 Key Market Developments
10.6.6 Key Strategies
10.7 Immune Therapeutics
10.7.1 Overview
10.7.2 Offerings
10.7.3 Key Financials
10.7.4 Business Segment & Geographic Overview
10.7.5 Key Market Developments
10.7.6 Key Strategies
10.8 Pfizer Inc
10.8.1 Overview
10.8.2 Offerings
10.8.3 Key Financials
10.8.4 Business Segment & Geographic Overview
10.8.5 Key Market Developments
10.8.6 Key Strategies
10.8 Bellicum Pharmaceuticals, Inc
10.8.1 Overview
10.8.2 Offerings
10.8.3 Key Financials
10.8.4 Business Segment & Geographic Overview
10.8.5 Key Market Developments
10.8.6 Key Strategies
10.9 Sorrento Therapeutics, Inc
10.9.1 Overview
10.9.2 Offerings
10.9.3 Key Financials
10.9.4 Business Segment & Geographic Overview
10.9.5 Key Market Developments
10.9.6 Key Strategies
10.10 Novartis.
10.10.1 Overview
10.10.2 Offerings
10.10.3 Key Financials
10.10.4 Business Segment & Geographic Overview
10.10.5 Key Market Developments
10.10.6 Key Strategies
